Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma
Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.
Read More
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer